KR102650364B1 - Composition for anti-oxidation, anti-inflammation, anti-atopy, anti-wrinkle and improvement of moisturizing comprising extract of Lycorisradiata - Google Patents

Abstract

The present invention relates to a composition containing aseptic acid as an active ingredient, and more specifically, to a composition for antioxidant, anti-inflammatory, anti-atopic, anti-wrinkle and moisturizing purposes containing extract of asperic acid. The composition containing the lithic acid extract according to the present invention exhibits antioxidant activity through ABTS free radical scavenging activity, anti-inflammatory activities such as nitric oxide inhibition and TNF-α inhibition activity, anti-atopic activity such as IL-8 inhibition activity, It has moisturizing properties such as enhancing hyaluronic acid and has anti-wrinkle activity such as inhibiting elastase activity, so it is expected to be highly utilized in cosmetics, pharmaceuticals, and health functional foods.

Description

Composition for anti-oxidation, anti-inflammation, anti-atopy, anti-wrinkle and improvement of moisturizing comprising aseptic acid extract as an active ingredient. extract of Lycoris radiata}

The present invention relates to a composition containing aseptic acid as an active ingredient, and specifically to a composition for antioxidant, anti-inflammatory, anti-atopic, anti-wrinkle, and moisturizing promotion containing extract of asperic acid.

The skin is a part of the body that is directly exposed to the external environment, and excessive exposure to ultraviolet rays or pollutants causes skin irritation and inflammatory reactions such as erythema, swelling, and itching. These skin problems not only cause cosmetic problems, but they are also known to cause pigmentation and promote the breakdown of skin elastic fibers, resulting in increased skin wrinkles, due to substances produced during the inflammatory reaction process. Additionally, it is known that skin damage is related to free radicals. Free radicals destroy cells, cut connective tissue in the dermal layer of the skin, or cause cross-linking, causing various problems such as wrinkle formation, skin cancer, cell killing, rheumatoid arthritis, atopic dermatitis, and acne.

Inflammation is a physiological response that protects the living body from the harmful surrounding environment, that is, invasion of foreign substances such as bacteria, and mechanical damage. This inflammatory phenomenon causes a large increase in various types of polynuclear leukocytes (PMNs) and immune substances, and these cells can provide treatment and defense by secreting various types of proteolytic enzymes and cytokines, which are inflammatory cell products. make it possible

Excessive inflammation causes damage to cells and connective tissue by proteolytic enzymes. Damage to connective tissue not only reduces skin elasticity and causes wrinkles, but also has a negative effect on cell regeneration and proliferation, resulting in rapid skin loss. It causes aging, and local erythema and swelling appear on the skin. If connective tissue is seriously damaged and the inflammatory response continues, restoring normal tissue structure and function becomes much more difficult.

Accordingly, to improve skin damage, a composition for improving antioxidant, anti-inflammatory and atopic dermatitis containing fermented black tea as a substance capable of suppressing free radical scavenging activity and inflammation (Korean Patent No. 1485896), and antioxidant containing a mixture of herbal medicines , anti-inflammatory and atopy prevention or treatment compositions (Korea registered patent no. 1654409), etc. are being studied.

Meanwhile, Lycoris radiata is a perennial bulbous plant belonging to the Amaryllid family and is also called a flower plant. The flower stem is about 30 to 50 cm long, the leaves are about 30 to 40 cm long, the width is about 1.5 cm long, and the length is about 1 m. The leaves come up in the fall, survive the winter and spring, and in early summer, all the leaves fall, the flower stalks rise, and red flowers bloom in early fall from September to October. Stone acid is known to have a detoxifying effect. The round root contains toxic alkaloids, so it is also called sinhwa, funerary flower, ghost flower, or piranha. It contains natural antibacterial substances and is used in adhesives, etc. It contains the toxic substance lycorine. It is known to affect skin diseases, etc.

Seoksan belongs to the Narcissus family, just like the Sargassum flower. However, while the selling price of the Sargassum flower is in the thousands of won, the cost of Seoksan is in the hundreds of won. There is a great possibility of using it as a material for food, medicine, and cosmetics, but research on it is minimal.

In order to improve the above problems, the present inventors studied the various effects of lithic acid extract and found that lithic acid extract exhibits antioxidant activity through ABTS free radical scavenging activity, DPPH radical scavenging activity or FRAP activity, and nitric oxide and TNF- The present invention was completed by confirming that it exhibits anti-inflammatory or anti-atopic activity by inhibiting α, IL-6 or IL-8, exhibits moisturizing effect by enhancing hyaluronic acid, and exhibits anti-wrinkle activity such as inhibiting elastase activity. did.

Accordingly, the purpose of the present invention is to provide a cosmetic composition, pharmaceutical composition, or health functional food composition for antioxidant, anti-inflammatory, anti-atopic, anti-wrinkle, and moisturizing promotion, which contains lithic acid extract as an active ingredient.

However, the technical problem to be achieved by the present invention is not limited to the problems mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the description below.

In order to achieve the above object, the present invention provides a cosmetic composition, pharmaceutical composition, or health functional food composition for antioxidant, anti-inflammatory, anti-atopy, anti-wrinkle, and moisturizing promotion, containing a lithic acid extract as an active ingredient.

In one embodiment of the present invention, the extract may be extracted using stone acid, water, C1 to C4 lower alcohol, or a mixed solvent thereof.

In another embodiment of the present invention, the lithic acid may be at least one part selected from the group consisting of leaves, stems, and roots of lithic acid.

In another embodiment of the present invention, the composition may exhibit ABTS free radical scavenging activity, DPPH radical scavenging activity, or FRAP activity.

In another embodiment of the present invention, the composition may inhibit the expression of one or more selected from the group consisting of nitric oxide, TNF-α, IL-6, and IL-8.

In another embodiment of the present invention, the composition can enhance hyaluronic acid synthesis.

In another embodiment of the present invention, the composition can inhibit the activity of elastase.

The composition containing the lithic acid extract according to the present invention exhibits antioxidant activity through ABTS free radical scavenging activity, anti-inflammatory activities such as nitric oxide inhibition and TNF-α inhibition activity, anti-atopic activity such as IL-8 inhibition activity, It has moisturizing properties such as enhancing hyaluronic acid and has anti-wrinkle activity such as inhibiting elastase activity, so it is expected to be highly utilized in cosmetics, pharmaceuticals, and health functional foods.

Figure 1 shows the results of preparing four types of extracts depending on the site and solvent based on quartz acid raw material.
Figure 2 shows the results of evaluating the solubility of the four extracts disclosed in Figure 1 in water and organic solvents.
Figure 3 shows the ABTS radical scavenging activity of four types of extracts prepared from seoksan.
Figure 4 shows the DPPH radical scavenging activity of four types of extracts prepared from seoksan.
Figure 5 shows the results of evaluating reducing power using iron ions after treatment with lithic acid extract.
Figure 6 shows the results of measuring the total polyphenol content of four types of extracts prepared from Seoksan.
Figure 7 shows the results of evaluating sample toxicity after treating four types of lithic acid extracts at a concentration range of 1.25 to 10 μg/mL.
Figure 8 shows the results of evaluating the activity of inhibiting the production of nitric oxide (NO), a pro-inflammatory substance, by treating four types of lithic acid extracts in a concentration range of 1.25 to 10 μg/mL.
Figure 9 shows the results of evaluating the activity of inhibiting the production of tumor necrosis factor-α (TNF-α), a pro-inflammatory substance, after treating four types of lithic acid extracts at a concentration range of 1.25 to 10 μg/mL.
Figure 10 shows the results of evaluating the activity of inhibiting the production of interleukin-6 (IL-6), a pro-inflammatory substance, after treating four types of lithic acid extracts at a concentration range of 1.25 to 10 μg/mL.
Figure 11 shows the results of evaluating sample toxicity after treating four types of lithic acid extracts in a concentration range of 1.25 to 10 μg/mL.
Figure 12 shows the results of evaluating the activity of inhibiting the production of IL-6, a substance related to atopy, after treating four types of lithic acid extracts at a concentration range of 1.25 to 10 μg/mL.
Figure 13 shows the results of evaluating the inhibition activity of IL-8 production, a substance related to atopy, after treating four types of lithic acid extracts.
Figure 14 shows the results of treating four types of lithic acid extracts and evaluating the activity of enhancing the production of hyaluronic acid (HA), a moisturizing factor, in HaCaT cells.
Figures 15 to 17 show the results of confirming the elastase inhibition effect when four types of quartz extract were treated for 10 minutes.
Figures 18 to 20 show the results of confirming the elastase inhibition effect when four types of quartz extract were treated for 20 minutes.
Figures 21 to 23 show the results of confirming the elastase inhibition effect when four types of lithic acid extract were treated for 30 minutes.
Figures 24 to 26 show the results of confirming the elastase inhibition effect when four types of quartz extract were treated for 130 minutes.

The present inventors studied the various effects of lithic acid extract and found that lithic acid extract exhibits antioxidant activity through ABTS free radical scavenging activity, DPPH radical scavenging activity, or FRAP activity, and nitric oxide, TNF-α, IL-6, or IL-8. The present invention was completed by confirming that it exhibits anti-inflammatory or anti-atopic activity by suppressing, exhibits moisturizing effect by enhancing hyaluronic acid, and exhibits anti-wrinkle effect by inhibiting elastase.

Accordingly, the present invention provides a cosmetic composition, pharmaceutical composition, or health functional food composition for antioxidant, anti-inflammatory, anti-atopy, anti-wrinkle, and moisturizing promotion, which contains lithic acid extract as an active ingredient.

The term “Lycoris radiata” used in the present invention refers to a perennial bulbous plant belonging to the Amaryllidaceae family. In the present invention, it may include leaves or roots, preferably Lycoris radiata, but is limited thereto. no.

The term “extract” used in the present invention refers to an extract obtained by extraction treatment of a substance, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, a crude product or purified product of the extract, or a mixture thereof, etc. This includes the extract itself and all formulations of the extract that can be formed using the extract.

The method for producing the extract of the present invention is not particularly limited, and it can be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include hot water extraction, ultrasonic extraction, filtration, reflux extraction, immersion extraction, high temperature and high pressure steam extraction, etc., which can be performed alone or by combining two or more methods. there is. The type of extraction solvent used in the present invention is not particularly limited, and any solvent known in the art can be used, including water, C1 to C4 lower alcohols such as methanol, ethanol, butanol, and mixed solvents thereof, etc. It can be a variety of organic solvents, including , but it is preferable to extract using ethanol.

As used in the present invention, the term “active ingredient” refers to an ingredient that can exhibit the desired activity alone or in combination with a carrier that is not active on its own.

The term “antioxidant” used in the present invention refers to the inhibition of oxidation and removes oxygen radicals generated in the body. Specifically, it can be understood as preventing oxidation through free radical scavenging activity. .

The term “anti-inflammatory” used in the present invention refers to the inhibition of inflammation, and in the present invention, it specifically induces inflammation through LPS treatment in a concentration range that is not toxic to cells and removes nitric oxide (NO), a pro-inflammatory substance. , it can be understood as showing inhibitory activity on tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) production.

The term “anti-atopy” used in the present invention refers to the inhibition of atopic dermatitis, a chronic inflammatory skin disease whose main symptoms are itching and dry skin, and indicates the activity of suppressing the production of IL-6 and IL-8, substances related to atopy. It can be understood.

The term “anti-wrinkle” used in the present invention can be understood as suppressing the formation of wrinkles, which is caused by a decrease in collagen or hyaluronic acid in the dermal layer.

The term “moisturizing enhancement” used in the present invention refers to maintaining moisture in the skin and making the skin elastic and soft. In the present invention, it refers to improving the moisture of the skin by enhancing the production of hyaluronic acid (HA), a moisturizing factor. It can be understood.

Through examples, the present invention has investigated the antioxidant, anti-inflammatory, anti-atopic, anti-wrinkle, and moisturizing-enhancing uses of quartz extract.

More specifically, in one embodiment of the present invention, the ABTS and DPPH radical scavenging activities of four types of extracts prepared from seoksan were confirmed, and the antioxidant activity of the seoksan extract was confirmed through evaluation of reducing power using iron ions and measurement of polyphenol content. (see Example 3).

In addition, in another example of the present invention, the anti-inflammatory activity of the lithic acid extract was confirmed by evaluating the activity of inhibiting the production of inflammatory substances NO, TNF-a, and IL-6 (see Example 4), and the atopy-related substances IL-6 6, the anti-atopic activity of the asperic acid extract was confirmed by evaluating the activity of suppressing the production of IL-8 (see Example 5). Additionally, the moisturizing enhancing activity of the asperic acid extract was confirmed by confirming the hyaluronic acid production enhancing activity (Example 6) reference).

In addition, in another example of the present invention, the anti-wrinkle activity of the quartz acid extract was confirmed by confirming that the quartz acid extract can inhibit the activity of elastase, which decomposes elastin, etc. (see Example 7).

From the above examples, it was confirmed through specific experiments that the composition of the present invention exhibits anti-oxidation, anti-inflammatory, anti-atopic, anti-wrinkle, and moisturizing enhancing uses. Accordingly, the composition according to the present invention has various uses as cosmetics, medicine, or health functions. It can be used in food, etc.

When the composition according to the present invention is used in the form of a cosmetic composition, in addition to the active ingredient, lithic acid extract, known compounds or natural substances can increase or reinforce the antioxidant, anti-inflammatory, anti-atopic, anti-wrinkle and moisturizing effects. Additional extracts may be included.

Meanwhile, in the composition of the present invention, the active ingredient may be included in any amount (effective amount) depending on the use, formulation, purpose of formulation, etc. to exhibit various antioxidant, anti-inflammatory, anti-atopic, anti-wrinkle and moisturizing activities. , a typical effective amount may be included within the range of 0.001% by weight to 99.99% by weight based on the total weight of the composition. Here, “effective amount” refers to the amount of active ingredient that can induce an effect. This effective amount can be determined experimentally within the scope of the ordinary ability of a person skilled in the art.

The cosmetic composition of the present invention can be manufactured in various forms. For example, the skin topical agent or cosmetic composition of the present invention can be manufactured in any formulation commonly prepared in the art, for example, solution, suspension, emulsion. It can be formulated as liquid, paste, gel, cream, ointment, lotion, powder, soap, cleansing, oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. Additionally, specifically, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutritional lotion, massage cream, nutritional cream, moisture cream, hand cream, essence, nutritional essence, pack, soap, shampoo, It may have a formulation selected from the group consisting of cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, lipstick, makeup base, foundation, press powder, and loose powder, but is not limited thereto.

The skin topical agent or cosmetic composition of the present invention may contain a carrier acceptable in the skin topical agent or cosmetic formulation in addition to the active ingredient. Here, “acceptable carrier in topical skin preparations or cosmetic preparations” refers to compounds or compositions already known and used that can be included in cosmetic preparations or compounds or compositions to be developed in the future that exhibit toxicity or instability beyond what the human body can adapt to upon contact with the skin. Or it refers to something that is not irritating. The carrier may be included in the skin topical agent or cosmetic composition of the present invention in an amount of about 1% to about 99.99% by weight based on the total weight, preferably about 5% by weight to about 99% by weight of the composition.

However, since the above ratio varies depending on the form of the above-mentioned skin topical agent or cosmetic of the present invention in which it is manufactured, its specific application site (face or hands), its preferred application amount, etc., the above ratio can be adjusted in any way. It should not be construed as limiting the scope of the invention.

Meanwhile, examples of the carrier include alcohol, oil, surfactant, fatty acid, silicone oil, wetting agent, moisturizing agent, viscosity modifier, emulsion, stabilizer, sunscreen, coloring agent, fragrance, etc. Alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, humectants, viscosity modifiers, emulsions, stabilizers, sunscreens, coloring agents, and fragrance compounds/compositions that can be used as the carrier are already known in the art. Therefore, a person skilled in the art can select and use the appropriate material/composition.

The composition according to the present invention can also be used in the form of an external skin preparation, and “external skin preparation” is an inclusive concept that generally includes all substances used for external skin application. Non-limiting examples of external skin preparation formulations include warning agents ( PLASTERS, LOTIONS, LINIMENTS, LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, OINTMENTS, FLUIDEXTRACTS, EMULSIONS ), SUSPESIONS, CAPSULES, CREAMS, soft and hard gelatin capsules, patches, or sustained-release preparations. The topical skin preparation according to the present invention may be a parenteral preparation formulated in solid, semi-solid or liquid form by adding commonly used inorganic or organic carriers, excipients and diluents. The preparation for parenteral administration may be a transdermal dosage form selected from the group consisting of drops, ointments, lotions, gels, creams, patches, sprays, suspensions and emulsions, but is not limited thereto.

When the composition according to the present invention is used in the form of a pharmaceutical composition, it may have functions of improving antioxidant, anti-inflammatory, anti-atopic, anti-wrinkle and moisturizing properties. The pharmaceutical composition of the present invention can be manufactured into tablets, pills, powders, granules, capsules, suspensions, solutions for internal use, emulsions, syrups, and aerosols according to conventional methods for improving antioxidant, anti-inflammatory, anti-atopic, anti-wrinkle, and moisturizing properties. It can be formulated in the form of sterilized injection solution, etc.

The pharmaceutical composition according to the present invention may contain a pharmaceutically effective amount of lithic acid extract alone or may contain one or more pharmaceutically acceptable carriers. At this time, pharmaceutically acceptable carriers are those commonly used in preparation, such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, and microcrystalline cellulose. , polyvinyl pyrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, etc., but are not limited thereto. In addition, in addition to the above ingredients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. may be additionally included.

The pharmaceutical composition of the present invention can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) depending on the desired method, and the dosage is determined by the patient's condition and weight, and the severity of the disease. It varies depending on the degree, drug form, administration route and time, but can be appropriately selected by a person skilled in the art.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type of patient's disease, severity, activity of the drug, and the drug. It can be determined based on factors including sensitivity to, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the field of medicine. The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.

Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, gender, condition, body weight, absorption of the active ingredient in the body, inactivation rate and excretion rate, type of disease, and concomitant drug. In general, 1 to 500 mg per kg of body weight can be administered daily or every other day, or divided into 1 to 3 times per day. However, since it may increase or decrease depending on the route of administration, gender, weight, age, etc., the above dosage does not limit the scope of the present invention in any way.

When the composition according to the present invention is used in the form of a health functional food composition, the health functional food of the present invention can be manufactured in various dosage forms, and unlike general drugs, it is made from food as a raw material and does not occur during long-term use of the drug. The health functional food of the present invention has the advantage of having no possible side effects and is highly portable, so it can be consumed as an adjuvant to enhance antioxidant, anti-inflammatory, anti-atopic, anti-wrinkle, and moisturizing activities.

The health functional food composition according to the present invention can be manufactured as food for specific health purposes and food with high medical and medical effects processed to efficiently exhibit bioregulatory functions in addition to food for nutritional purposes. The food may be, in some cases, functional food, It can be used interchangeably as health food and health supplement, and can be manufactured in various forms such as tablets, capsules, powder, granules, liquid, and pills to achieve useful effects.

The health functional food of the present invention may contain additional ingredients that are commonly used in food compositions to improve smell, taste, vision, etc. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, etc. Additionally, it may contain minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), and copper (Cu). Additionally, it may contain amino acids such as lysine, tryptophan, cysteine, and valine. In addition, preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dihydroacetate, etc.), disinfectants (bleaching powder, high bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxy toluene (BHT) ), etc.), colorants (tar colors, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (MSG monosodium glutamate, etc.), sweeteners (dulcine, cyclemate, saccharin, sodium, etc.), Food additives such as flavorings (vanillin, lactones, etc.), leavening agents (alum, D-potassium hydrogen tartrate, etc.), strengthening agents, emulsifiers, thickeners (grease), coating agents, gum base agents, anti-foam agents, solvents, improvers, etc. can be added. The additives can be selected depending on the type of food and used in an appropriate amount.

When using the health functional food of the present invention as a food additive, it can be added as is or used together with other foods or food ingredients, and can be used appropriately according to conventional methods.

In the health functional food of the present invention, the content of lithic acid extract is not particularly limited and may vary depending on the condition of the administration subject, the type of specific disease, the degree of progression, etc. If necessary, it can also be included in the total amount of the food.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.

[Example]

Example 1. Experimental method

1-1. Preparation of lithic acid extract

Seoksan (biological) raw materials delivered from Yeonggwang-gun Agricultural Technology Center were separated from leaves and roots to evaluate skin physiological activity, and then each extract was prepared using water and 70% ethanol as follows.

First, the hot water extraction of lithic acid was carried out for 4 hours through the decoction method by adding 20 times the amount of distilled water to 50 g of pulverized lithic acid parts (leaves and roots). The extract was removed from residues using gauze for filtration, concentrated with a vacuum concentrator, removed from residues through centrifugation, and then freeze-dried after secondary filtration to become a hot water extract (HW) with all moisture removed. It was prepared.

Next, ethanol extraction of silicic acid was carried out for 4 hours through the reflux method (60°C) by adding 10 times 70% ethanol to 50 g of pulverized silicic acid parts (leaves and roots). The extract was removed from residues using gauze for filtration, concentrated with a vacuum concentrator, removed from residues through centrifugation, and then subjected to secondary filtration and freeze-dried to prepare an ethanol extract (ethanol extract. E) from which all moisture was removed. It has been done.

1-2. Antioxidant activity evaluation method

First, to confirm the ABTS free radical scavenging activity, 7.4mM ABTS solution and 2.6mM potassium persulphate solution were left in the dark for more than 12 hours to form blue-green radicals, and then diluted to have an absorbance value of 1.5 at 734 nm to create ABTS working solution. It was manufactured and used in experiments. 10 μL of sample diluted by concentration was added to this solution and reacted at room temperature for 30 minutes to measure the change in absorbance of the reaction solution at 734 nm. The results were expressed as inhibitory activity (%) relative to the ABTS working solution. Meanwhile, the ABTS radical scavenging activity of the samples treated at each concentration was calculated as the IC ₅₀ (Half maximal inhibitory concentration) value, and the antioxidant activity of the samples was compared and evaluated by comparing the IC ₅₀ value with ascorbic acid used as a standard substance.

- ABTS radical inhibition activity (%) = (Blank O.D-Sample O.D)/(Blank O.D)Х100

- Blank O.D: Absorbance after reaction of blank sample solution

- Sample O.D: Absorbance after reaction of sample solution

Next, to confirm the DPPH free radical scavenging activity, 10 μL of sample was added to 0.2 mM DPPH radical solution, reacted at room temperature for 30 minutes, and the change in absorbance of the reaction solution was measured at 514 nm. The results were expressed as inhibitory activity (%) relative to the DPPH working solution, and the DPPH radical scavenging activity of samples treated by concentration was calculated as the IC ₅₀ (Half maximal inhibitory concentration) value. As with ABTS, DPPH radical scavenging activity was evaluated by comparing the IC ₅₀ value with ascorbic acid, a standard substance.

- DPPH radical inhibitory activity (%)=(Blank O.D-Sample O.D)/(Blank O.D)Х100

- Blank O.D: Absorbance after reaction of blank sample solution

- Sample O.D: Absorbance after reaction of sample solution

Next, in order to confirm the evaluation of reducing power using iron ions, the Ferric reducing antioxidant power (FRAP) assay uses the principle of converting ferric ions (Fe ³⁺ ) into ferrius ions (Fe ²⁺ ) by the ferrous tripyridyl triazine complex. This is a method of measuring the metal ion scavenging activity in a sample. FRAP reagent was prepared by sequentially mixing 300 mM acetate buffer, 10 mM 2,4,6-Tris(2-pyridyl)-s-triazine (TPTZ), FeCl ₃ , and distilled water in a ratio of 10:1:1:1.2. , 200 μL of this solution and 10 μL of samples of each concentration were reacted at room temperature for 4 minutes, and the change in absorbance of the reaction solution was measured at 593 nm. A calibration curve was prepared using the standard material, Iron(II) sulfate heptahydrate (FeSO ₄ ·10 H ₂ O), and the FRAP activity of the sample was expressed as mM ferrous sulfate equivalents (FSE)/mL relative to the standard material.

Next, to measure the total polyphenol content using the Folin-Ciocalteu method, 10 μL of 2% Na ₂ CO ₃ was added to 10 μL of the sample to create alkaline conditions, followed by reaction for 3 minutes and 50% Folin-Ciocalteus' solution. 200 μL of reagent was added and reacted for 30 minutes, then measured at 750 nm. A calibration curve was prepared using gallic acid as a standard material, and the total polyphenol compound content of the sample was expressed in concentration (mg/g).

1-3. Methods for assessing anti-inflammatory activity

First, to evaluate sample toxicity for RAW 264.7 cells, RAW 264.7 cells, a mouse macrophage cell line, were purchased from the Korean Cell Line Bank (KCLB) and cultured in DMEM medium supplemented with 10% FBS and 1% P/S. (hereinafter referred to as RAW culture medium) was used, and subcultured once every 2 to 3 days in an incubator maintained at 37°C and 5% CO ₂ and used in the experiment. RAW 264.7 cells were plated on a 96 well plate at 4×10 ⁴ cells/well or 2×10 ⁵ cells/well and cultured in a 5% CO ₂ incubator at 37°C for 24 hours to stabilize the cells. After removing all cell supernatants, 160 μL of DMEM medium without FBS and 20 μL of appropriately diluted samples were added. After 30 minutes, LPS (1 μg/mL) was added as an inflammatory substance and re-cultured for 24 hours. . Afterwards, the supernatant was removed again, 100 μL of 0.1 mg/mL 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) solution was added, and cultured in an incubator for 30 minutes. After removing the MTT solution, 100 μL of DMSO was added to dissolve the resulting pigment and the absorbance was measured at 550 nm. The toxicity of RAW 264.7 cells by the sample was expressed as cell viability (%) relative to the untreated group.

Next, to evaluate TNF-α and IL-6 inhibitory activity using ELISA, RAW 264.7 cells were plated on a 96 well plate at 4 × 10 ⁴ cells/well and cultured in a 37°C, 5% CO ₂ incubator for 24 hours. was stabilized. After removing all cell supernatants, 160 μL of DMEM medium without FBS and 20 μL of appropriately diluted samples were added. After 30 minutes, LPS (1 μg/mL) was added as an inflammatory substance and recultured for 24 hours. . The content of inflammatory cytokines TNF-α and IL-6 released in the cell culture supernatant was measured by sandwich ELISA method and calculated as production amount (pg/mL) through a standard curve created using lyophilized recombinant protein provided by the manufacturer. Meanwhile, as a positive control (PC), dexamethasone (20 μg/mL) was treated instead of the sample, and was used to compare the inhibitory activity of TNF-α and IL-6 with the sample.

Next, to evaluate the nitric oxide inhibitory activity using the Griess method, RAW 264.7 cells were plated at 4 × 10 ⁴ cells/well in a 96 well plate and cultured in a 5% CO ₂ incubator at 37°C for 24 hours to stabilize the cells. After removing all cell supernatants, 160 μL of DMEM medium without FBS and 20 μL of appropriately diluted samples were added. After 30 minutes, LPS (1 μg/mL) was added as an inflammatory substance and recultured for 24 hours. . The content of NO released from the cell culture supernatant was measured by the Griess method and quantified in μM using sodium nitrite (NaNO ₂ ). Meanwhile, as a positive control (PC), L-NAME (50 μg/mL) was treated instead of the sample, and was used to compare the nitric oxide inhibitory activity with the sample.

1-4. Anti-atopic activity evaluation method

First, to evaluate the sample toxicity of HaCaT cells, HaCaT human skin keratinocyte cells for evaluating anti-atopic activity were purchased from the Korea University Functional Food Laboratory and used in experiments. Cells used DMEM medium supplemented with 10% FBS and 1% P/S, and were subcultured once every 2 to 3 days in an incubator maintained at 37°C and 5% CO ₂ and used in experiments.

HaCaT cells were plated on a 96-well plate at 2×10 ⁴ cells/well and cultured in a 37°C, 5% CO ₂ incubator to stabilize the cells. After 24 hours, all culture supernatants were removed and then cultured in DMEM without FBS. 200 μL of medium was added and cultured for 24 hours. Afterwards, all culture supernatants were removed, 160 μL of DMEM medium without FBS and 20 μL of sample diluted to an appropriate concentration were added and re-cultured. After 30 minutes, TNF-α and IFN-γ (T +I) was added at 10 ng/mL each and then cultured for 24 hours. Evaluation of cytotoxicity by the sample was measured by the MTT method as mentioned above, and was expressed as cell viability (%) relative to the untreated sample. Meanwhile, as a positive control (PC), dexamethasone (20 μg/mL) was treated instead of the sample, and was used to compare the IL-6 and IL-8 inhibitory activity with the sample.

Next, to evaluate IL-6 and IL-8 inhibitory activity using ELISA, HaCaT cells were plated on a 96-well plate at 2×10 ⁴ cells/well and cultured in a 37°C, 5% CO ₂ incubator to stabilize the cells. After 24 hours, all culture supernatants were removed, then 200 μL of DMEM medium without FBS was added and cultured for 24 hours.

Afterwards, all culture supernatants were removed, 160 μL of DMEM medium without FBS and 20 μL of sample diluted to an appropriate concentration were added and re-cultured. After 30 minutes, TNF-α and IFN-γ (T +I) was added at 10 ng/mL each and then cultured for 24 hours. The culture supernatant was recovered, and the contents of IL-6 and IL-8, which are cytokines released into the supernatant, were measured using R&D Systems' ELISA set, and the production amount (pg/ mL) was calculated. Meanwhile, as a positive control (PC), dexamethasone (20 μg/mL) was treated instead of the sample, and was used to compare the IL-6 inhibitory activity with the sample.

1-5. How to evaluate moisturizing efficacy

First, to evaluate hyaluronic acid production using ELISA, HaCaT cells were plated on a 96-well plate at 2×10 ⁴ cells/well and cultured in an incubator at 37°C with 5% CO ₂ to stabilize the cells for 24 hours. Afterwards, all culture supernatants were removed, and then 180 μL of DMEM medium without FBS and 20 μL of samples diluted to an appropriate concentration were added and re-cultured. The content of hyaluronic acid (HA) released into the cell culture supernatant was measured using an ELISA set from R&D Systems, and the content (ng/mL) was calculated using a standard curve created using the provided standard material.

1-6. statistical processing

The experimental results were calculated by calculating the mean and standard deviation and expressed as mean ± SD. Statistical analysis of the experimental results was performed using the SPSS statistical program (Statistical Package for the Social Science, Ver. 12.0, SPSS Inc., Chicago, IL). , USA) and tested for significance at the p<0.05, p<0.01, and p<0.001 levels, respectively.

Example 2. Solubility evaluation of lithic acid extract

As shown in Figure 1, the lithic acid extract prepared in Example 1-1 was ① Lycoris radiata Root Hot Water extract (LR-R-HW), ② 70% root ethanol extract (Lycoris radiata Root Ethanol extract, LR) -R-E), ③ leaf hot water extract (Lycoris radiata Leaf Hot Water extract, LR-L-HW), and ④ leaf 70% ethanol extract (Lycoris radiata Leaf Ethanol extract, LR-L-E).

As a result of evaluating the solubility in water and organic solvents of the four types of extracts prepared, as shown in Figure 2, the leaf hot water extract (LR-L-HW) had excellent water solubility, while the root hot water extract (LR -R-HW), root ethanol extract (LR-R-E), and leaf ethanol extract (LR-L-E) were all confirmed to have excellent solubility in DMSO.

Example 3. Confirmation of antioxidant activity according to treatment with lithic acid extract

3-1. Free radical scavenging activity

The radical scavenging activity of four types of extracts prepared from seoksan was evaluated in the concentration range of 1.25 to 5 mg/mL, as shown in Figures 3 and 4, and it was confirmed that the activity increased in a concentration-dependent trend in all samples. did.

In addition, in order to compare the relative antioxidant activity, IC ₅₀ (half maximal inhibitory concentration), which is the concentration showing 50% inhibitory activity, was calculated. As shown in Figure 3, ABTS radical scavenging activity was found to be higher than that of the leaf ethanol extract (5.8 mg/ mL) > leaf hot water extract (6.6 mg/mL) > root hot water extract (23.0 mg/mL) > root ethanol extract (23.3 mg/mL).

Furthermore, the results of DPPH radical scavenging activity showed excellent activity in the ethanol extract of leaves (4.8 mg/mL) and hot water extract (6.8 mg/mL), similar to ABTS, while the hot water extract of roots (nd) and ethanol extract (nd) No IC ₅₀ value was derived, confirming that the antioxidant activity of Aspergillus root was relatively weak.

3-2. Evaluation of reducing power using metal ions and measurement of total polyphenol content

First, in a reducing power test using iron ions, four types of lithic acid extracts were evaluated in the concentration range of 1.25 to 5 mg/mL, and showed a concentration-dependent increase in activity as shown in Figure 5. Additionally, compared to the control material ferrous sulfate (FeSO ₄ ), FRAP activity was as follows: leaf ethanol extract (156.7 mM/g) > leaf hot water extract (110.7 mM/g) > root ethanol extract (16.2 mM/g) > root. It was confirmed in the order of hot water extract (8.8 mM/g).

In addition, as a result of measuring the content of polyphenols, which are generally known to be excellent in antioxidant activity, compared to gallic acid used as a standard material as shown in FIG. extract (31.4 mg/g; 3.1%) > root hot water extract (27.9 mg/g; 2.8%) > leaf hot water extract (15.6 mg/g; 1.6%) > root ethanol extract (6.0 mg/g; 0.6%). It was confirmed that it appeared high.

Example 4. Confirmation of anti-inflammatory activity according to treatment with lithic acid extract

4-1. Sample toxicity assessment results in RAW 264.7 cells

Before evaluating the immune-enhancing activity of the five samples, we attempted to evaluate cytotoxicity using the RAW 264.7 cell line. It was confirmed that samples showing a cell viability of more than 80% compared to the negative control (NC) were not toxic. In addition, as a result of evaluating the sample toxicity of four types of lithic acid extract in the concentration range of 1.25 to 10 μg/mL, compared to the LPS control group, as shown in Figures 7a and 7b, the root hot water extract was 104.9 to 110.5% and the leaf hot water extract was 103.5 to 103.5%. Cell viability was 117.0%, root ethanol extract 105.6~117.8%, and leaf ethanol extract 109.9~128.8%, confirming that all samples were not cytotoxic within the test concentration.

4-2. Confirmation of activity to inhibit the production of inflammatory substances

Inducing inflammation through LPS treatment in a concentration range that is not toxic to cells and evaluating the activity of suppressing the production of pro-inflammatory substances such as nitric oxide (NO), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) The results are shown in Figures 8 to 10, respectively.

First, as shown in Figures 8a and 8b, the NO inhibition activity evaluation results showed that the LPS-treated group (LPS) produced 23.4 μM of NO, which was about 2.1 μM compared to the untreated group (negative control, NC; 2.1 μM). It was confirmed to be a statistically significant (p<0.001) increase of 11.0 times. The positive control (PC) treated with L-NAME (50 μM), which is already known to have excellent NO inhibition effect, showed NO production of 7.4 μM, which was statistically significant (p <0.001) was confirmed to have inhibitory activity. In addition, all lithic acid extracts showed a statistically significant NO inhibition effect in the concentration range of 1.25 to 10 μg/mL, with leaf ethanol extract (21.9 to 98.3% inhibition) ≒ leaf hot water extract (23.2 to 97.2% inhibition) ) > Root ethanol extract (11.2~94.6% inhibition) > Root hot water extract (2.6~74.9% inhibition) was confirmed to have excellent NO suppression activity in the order of ), the best NO inhibitory activity was confirmed.

In addition, as shown in Figures 9a and 9b, the results of evaluating the TNF-α inhibitory activity showed that the LPS-treated group produced 75.4 to 74.8 ng/mL of TNF-α, compared to the NC control group (0.04 ng/mL). This was confirmed to be a statistically significant (p<0.001) increase of approximately 1922 times. The PC control group treated with 20 μg/mL of dexamethasone produced 42.2 ng/mL of TNF-α, which was confirmed to have a statistically significant (p<0.001) inhibitory activity of about 43.6-44.0% compared to the LPS control group. In addition, all lithic acid extracts showed an increase in TNF-α inhibitory activity in a concentration-dependent manner, as follows: leaf ethanol extract (13.5-44.1% inhibition) > leaf hot water extract (16.0-34.3% inhibition) > root ethanol extract ( The TNF-α inhibitory activity was evaluated to be excellent in the order of 7.7~30.1% inhibition) > root hot water extract (9.0~17.2% inhibition), and in conclusion, among the four types of lithic acid extracts, the leaf ethanol extract (LR-L-E) was the best. TNF-α inhibitory activity was confirmed.

Furthermore, as shown in Figures 10a and 10b, in the results of evaluating IL-6 inhibitory activity, the LPS treatment group showed IL-6 production of 1012.7 to 1425.1 pg/mL, compared to the NC control group (23.5 pg/mL). It was confirmed to be a statistically significant (p<0.05 or p<0.01) increase of approximately 43.1 to 60.7 times. The PC control group treated with 20 μg/mL of dexamethasone showed IL-6 production of 547.0 pg/mL, which was confirmed to have a statistically significant (p<0.05 or p<0.001) inhibitory activity of about 47.1~62.6% compared to the LPS control group. . The hot water extracts (roots and leaves) of Seoksan did not show statistically significant IL-6 inhibitory activity compared to the LPS control group in all concentration ranges (p>0.05). In the ethanol extract of Seoksan root, a significant (p<0.05) IL-6 inhibitory activity of 19.7~28.3% compared to the LPS control was confirmed in the concentration range of 2.5~10 μg/mL, and in the ethanol extract of leaves, 1.25~10 μg/mL. It was confirmed that the ethanol extract of the leaf had a relatively superior activity compared to the ethanol extract of the root as it showed a significant (p<0.05 or p<0.01) IL-6 inhibitory activity in the range of mL, and in conclusion, 4 Among the lithic acid extracts of the species, the ethanol extract of the leaves (LR-L-E) was found to have the best IL-6 inhibitory activity.

Example 5. Confirmation of anti-atopic activity according to treatment with lithic acid extract

5-1. Sample toxicity evaluation results in HaCaT cells

As a result of evaluating the sample toxicity of four types of lithic acid extract in the concentration range of 1.25 to 10 μg/mL, as shown in Figures 11a and 11b, compared to the TNF-α+IFN-γ (T+I) treatment group, the root hot water extract All samples were evaluated as non-toxic, with cell survival rates of 100.9~108.6%, leaf hot water extract 103.2~123.8%, root ethanol extract 105.9~121.8%, and leaf ethanol extract 105.3~121.8%.

5-2. Confirmation of inhibitory activity of atopic dermatitis-related substances

The results of evaluating the activity of inducing atopy and suppressing the production of IL-6 and IL-8, atopy-related substances, through T+I treatment in a concentration range that is not toxic to cells are shown in Figures 12 and 13, respectively.

First, as shown in Figures 12a and 12b, in the results of evaluating IL-6 inhibitory activity, the T+I treatment group showed IL-6 production of 1779.3 to 1810.2 pg/mL, which is about 15.6 compared to the NC control group (113.8 pg/mL). It showed a statistically significant (p<0.001) increase of ~15.8 times. In addition, the PC control group treated with 20 μg/mL of dexamethasone showed IL-6 production of 1121.9 pg/mL, which was confirmed to be a statistically significant (p<0.001) inhibitory activity of about 39.5-40.6% compared to the T+I control group. . In the case of Seoksan hot water extract, the roots did not show statistically significant IL-6 inhibitory activity compared to the T+I treatment group in all concentration ranges (p>0.05), but in the case of leaves, the significance was 10.7% at a concentration of 10 μg/mL. It showed IL-6 inhibitory activity. In the case of ethanol extract of sulfate, a significant IL-6 inhibitory activity of 11.9~23.2% was confirmed in roots compared to the T+I control group in the concentration range of 1.25~10 μg/mL, and in leaves, 16.1~28.3% in the same concentration range. It was confirmed that the leaf ethanol extract had relatively better IL-6 inhibitory activity than the root ethanol extract. In conclusion, among the four types of lithic acid extracts, the ethanol extract of leaves (LR-L-E) was found to have the best IL-6 inhibitory activity.

Next, as shown in Figures 13a and 13b, in the results of evaluating the IL-8 inhibitory activity, the T+I treatment group showed IL-8 production of 1441.8 to 1487.1 pg/mL, which is about 4.7 compared to the NC control group (305.7 pg/mL). It was confirmed to be a statistically significant (p<0.001) increase of ~4.9 times. The PC control group treated with 20 μg/mL of dexamethasone showed IL-8 production of 537.2 pg/mL, which was confirmed to have a statistically significant inhibitory activity of about 79.6 to 80.4% compared to the T+I treatment group (p<0.001). IL-8 inhibitory activity increased in a concentration-dependent trend in all lithic acid extracts: leaf ethanol extract (30.2~70.8% inhibition) > root ethanol extract (15.5~57.7% inhibition) > leaf hot water extract (-2.6~42.6%) Inhibition) > Root hot water extract (-3.0~21.3% inhibition) was evaluated as having excellent IL-8 inhibitory activity in the order. In conclusion, among the four types of lithic acid extracts, the ethanol extract of leaves (LR-L-E) was found to have the best IL-6 inhibitory activity.

Example 6. Confirmation of moisturizing enhancement activity according to treatment with quartz extract

As shown in Figures 14a and 14b, the results of evaluating the activity to enhance the production of hyaluronic acid (HA), a moisturizing factor, in HaCaT cells showed an amount of HA production of 259.9 to 289.1 ng/mL in the untreated NC control group, which is a well-known moisturizing factor. In the PC control group treated with the promoting substance N-acetylglucosamine (5 mg/mL), a significant (p<0.001) HA production enhancing activity was confirmed at 469.0 ng/mL, approximately 1.62 to 1.81 times that of the NC control group. Concentration-dependent HA production enhancing activity was confirmed in all lithic acid extracts: leaf hot-water extract (1.15-1.95-fold increase) > root hot-water extract (0.95-1.87-fold increase) > leaf ethanol extract (1.25-1.78-fold increase) > root The HA production enhancing activity was found to be excellent, followed by ethanol extract (0.94-1.28 times increase). In conclusion, among the four types of lithic acid extracts, the highest HA production enhancing activity was confirmed in the leaf hot water extract (LR-L-HW).

Example 7. Confirmation of anti-wrinkle activity according to treatment with lithic acid extract

According to recent studies, increased activity of elastase, which breaks down elastin, is known to contribute to the formation of skin wrinkles by reducing elastic fibers in the skin. Accordingly, in order to confirm the anti-wrinkle activity of the quartz acid extract, the elastase inhibitory activity of the quartz acid extract was confirmed.

Specifically, the seoksan extract was prepared in the same manner as in Example 1-1, except that the roots of seoksan were used as is, but the leaves of seoksan were replaced with the stems of seoksan, and the sample was treated with distilled water (DIW) as a control. ), 1% DMSO, and ursolic acid in 10% DMSO/DIW were used.

First, mix the sample (20 μL), 2 mM Tris-HCl buffer (pH 8.0) (55 μL), and 0.8 mM STANA solution (125 μL) in a 96-well plate, and shake using a plate shaker to obtain O.D (390 nm). The value was confirmed. Afterwards, the plate was sealed, incubated at 37°C for 15 minutes, and 50 μL of 1 μg/Ml Elastase was added. Afterwards, the plate was shaken using a plate shaker to confirm the O.D (390 nm) value. The plate was sealed again and incubated at 37°C for 10, 20, 30, and 130 minutes to check the O.D. (390 nm) value. The specific experimental conditions and experimental results were as shown in Figures 15 to 26 below.

As a result, it was confirmed that the elastase inhibition rate increased in a concentration-dependent manner for each extract, and that the elastase inhibition rate decreased as the treatment time (10, 20, 30, and 130 minutes) increased.

In addition, regardless of the treatment time (10, 20, 30, 130 minutes), the elastase inhibition effect is excellent in the order of lithic acid stem (EtOH) > lithic acid root (EtOH) > lithic acid root (hot water) > lithic acid stem (hot water). was able to confirm.

Manufacturing example

The composition according to the above example was formulated into an emollient lotion, external skin preparation, capsule, or beverage.

Preparation Example 1. Preparation of flexible lotion

The manufacturing example of the softening lotion containing the composition of Example 2-1 is shown in [Table 1] below.

ingredient Content (% by weight) Composition of Example 2-1 5.00 glycerin 5.00 Butylene glycol 2.00 propylene glycol 2.00 Polyoxyethylene (60) hydrogenated castor oil 2.00 ethanol 10.0 Triethanolamine 3.00 antiseptic 0.50 pigment 0.20 Spices 0.30 Purified water 70.0 Sum 100

Preparation Example 2. Preparation of external skin preparation

Preparation examples of external skin preparations containing the composition of Example 2-1 are shown in Table 2 below.

ingredient Content (% by weight) Composition of Example 2-1 5.10 glycerin 5.00 Butylene glycol 0.60 Hyaluronic Acid Extract 0.02 beta glucan 4.00 carbomer 0.15 Caprylic Capric Triglyceride 0.50 squalene 0.20 stearyl glucoside 5.00 stearyl alcohol 4.00 Sorbitan Stearate 0.10 Purified water 75.33 Sum 100

Preparation Example 3. Preparation of capsules

Manufacturing examples of capsules containing the composition of Example 2-1 are shown in Table 3 below.

ingredient Content (% by weight) Composition of Example 2-1 50 starch 23 lactose 23 Talc One Stearin Magnesium 3 Sum 100

Preparation Example 4. Preparation of beverage

An example of the preparation of a beverage containing the composition of Example 2-1 is shown in Table 4 below.

ingredient Content (% by weight) Composition of Example 2-1 7 vitamin 8 Dietary Fiber 6 high fructose corn syrup 20 emulsifier 60 Lemon scent 7 Purified water 5 Sum 100

The description of the present invention described above is for illustrative purposes, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical idea or essential features of the present invention. will be. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive.

Claims (13)

A cosmetic composition for antioxidant, anti-inflammatory, anti-atopic, anti-wrinkle, and moisturizing promotion, containing lithic acid extract as an active ingredient.
According to paragraph 1,
A cosmetic composition, wherein the extract is obtained by extracting stone acid using water, C1 to C4 lower alcohol, or a mixed solvent thereof.
According to paragraph 1,
A cosmetic composition, wherein the stone acid is at least one part selected from the group consisting of leaves, stems, and roots of stone mountain.
According to paragraph 1,
A cosmetic composition, characterized in that the composition exhibits ABTS free radical scavenging activity, DPPH radical scavenging activity, or FRAP (Fluorescence Recovery After Photobleaching) activity.
According to paragraph 1,
The composition is characterized by inhibiting the production of one or more selected from the group consisting of nitric oxide, tumor necrosis factor-α (TNF-α), Interleukin-6 (IL-6), and Interleukin-8 (IL-8). A cosmetic composition.
According to paragraph 1,
A cosmetic composition, characterized in that the composition promotes hyaluronic acid (HA) synthesis.
According to paragraph 1,
A cosmetic composition characterized in that the composition inhibits the activity of elastase.
A pharmaceutical composition for anti-inflammatory, anti-atopic and anti-wrinkle use, comprising lithic acid extract as an active ingredient.
According to clause 8,
A pharmaceutical composition, wherein the extract is obtained by extracting stone acid using water, C1 to C4 lower alcohol, or a mixed solvent thereof.
According to clause 8,
A pharmaceutical composition, wherein the lithic acid is at least one part selected from the group consisting of leaves, stems and roots of lithic acid.
A health functional food composition for antioxidant, anti-inflammatory, anti-atopic, anti-wrinkle and moisturizing promotion, containing lithic acid extract as an active ingredient.
According to clause 11,
The extract is a health functional food composition, characterized in that silicic acid is extracted using water, C1 to C4 lower alcohol, or a mixed solvent thereof.
According to clause 11,
A health functional food composition, wherein the stone acid is at least one part selected from the group consisting of leaves, stems, and roots of stone acid.